FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hedy Kindler

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Valerie W Rusch; Hedy L Kindler
MARS: A Sense of Perspective and an Inconvenient Truth.
Zacariah E Labby; Samuel G Armato; James J Dignam; Hedy L Kindler; Christopher Straus; Anna K Nowak
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
Zacariah E Labby; Samuel G Armato; James J Dignam; Arman Hasani; Hedy L Kindler; Anna K Nowak
Optimization of response classification criteria for patients with malignant pleural mesothelioma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hedy Kindler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Valerie W Rusch; Hedy L Kindler
MARS: A Sense of Perspective and an Inconvenient Truth.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(5):e49-50.
2013: Zacariah E Labby; Samuel G Armato; James J Dignam; Hedy L Kindler; Christopher Straus; Anna K Nowak
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(4):478-86.
2012: Zacariah E Labby; Samuel G Armato; James J Dignam; Arman Hasani; Hedy L Kindler; Anna K Nowak
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(11):1728-34.
2012: Nathan M Mollberg; Ravi Salgia; Aliyah N Husain; Hedy L Kindler; Yalini Vigneswaran; Cynthia Warnes; Wickii T Vigneswaran
Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma.
The Annals of thoracic surgery 2012;94(4):1086-92.
2012: Nicholas P Campbell; David R Gandara; Barbara J Gitlitz; Marianna Koczywas; Rangesh Kunnavakkam; Natasha Leighl; Walter M Stadler; Sachdev P Thomas; Mark D Vincent; Everett E Vokes; Edem Agamah; Hedy L Kindler
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Lung cancer (Amsterdam, Netherlands) 2012;78(1):76-80.
2012: Hedy L Kindler; Marianna N Koczywas; Lee M Krug; Charles Lu; David I Quinn; Walter M Stadler; James P Stevenson; David A Taber; Nicholas J Vogelzang; Kathy S Albain; Samuel G Armato; Julie R Brahmer; Helen X Chen; David R Gandara; Pasi A Janne; Theodore G Karrison; Everett E Vokes
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(20):2509-15.
2012: Manish R Sharma; Bethany G Sleckman; Walter M Stadler; David Taber; Everett E Vokes; James A Wallace; Kristen Wroblewski; James A Knost; Sanjiv Modi; Blase N Polite; Hedy L Kindler
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
Investigational new drugs 2012;30(3):1211-5.
2012: Arkadiusz Z Dudek; Lydia Hodgson; Hedy L Kindler; Robert A Kratzke; Gregory A Otterson; Herbert Pang; Everett E Vokes
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(4):755-9.
2012: Dorothy Romanus; Deborah Schrag; Jane Weeks; Laura Archer; Ethan Basch; Hedy L Kindler; Donna Niedzwiecki
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Journal of pain and symptom management 2012;43(2):205-17.
2012: Federico Innocenti; Chen Jiang; Hedy L Kindler; Michiaki Kubo; Liang Li; Howard L McLeod; Taisei Mushiroda; Yusuke Nakamura; Kouros Owzar; Nancy L Cox; Patrick Evans; Paula Friedman; Kathleen M Giacomini; Dylan Glubb; Richard M Goldberg; Donna Hollis; Herbert Hurwitz; Richard L Schilsky; Liewei Wang; Hitoshi Zembutsu; Mark J Ratain
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):577-84.
2012: George B Carey; Paul Dave; Thomas Hensing; Aliya N Husain; Archana Kanteti; Stephanie Kazantsev; Hedy L Kindler; Ravi Madduri; Brigitte Raumann; Cleo E Rolle; Ahad Sadiq; Adam Starkey; Mosmi Surati; Wickii T Vigneswaran; Everett E Vokes; Samuel G Armato; Neil Bahroos; Ravi Salgia
Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma.
BMJ open 2012;2(5):.
2012: Nathan M Mollberg; Nigel M Parsad; Ravi Salgia; William F Sensakovic; Jonathan Silverstein; Janani Vigneswaran; Samuel G Armato; Hedy L Kindler; Wickii T Vigneswaran
Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma.
International surgery 2012;97(1):65-70.
2012: Satish Kalari; Archana Kanteti; Prasad Kanteti; Rajani Kanteti; Hedy L Kindler; Wenli Ma; Nagabhushan Moolky; Evgeny Berdyshev; Donghong He; Aliya N Husain; Srikanth Pendyala; Cleo Rolle; Ravi Salgia; Viswanathan Natarajan
Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation.
PloS one 2012;7(9):e45330.
2011: Manish A Shah; Laura Tang; John J Wright; Margaret M Kemeny; Hedy L Kindler; Derek G Power; Marinela Capanu; Kyle D Holen; David H Ilson; David P Kelsen
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
Investigational new drugs 2011;29(6):1475-81.
2011: Daniel V T Catenacci; Gustavo Cervantes; Mohamed El Dinali; Essam El-Hashani; David A Frank; Tatyana A Grushko; Rifat Hasina; Les Henderson; Heather Huet; Rajani Kanteti; Theodore Karrison; Woo Ho Kim; Hedy L Kindler; Erik A Nelson; Olufunmilayo Olopade; Michele Sanicola; Tanguy Seiwert; Maria Tretiakova; Everett Vokes; Soheil Yala; Yung-Jue Bang; Johannes Brägelmann; Ravi Salgia
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Cancer biology & therapy 2011;12(1):9-46.
2011: Daniel V T Catenacci; Mark Kozloff; Hedy L Kindler; Blase Polite
Personalized colon cancer care in 2010.
Seminars in oncology 2011;38(2):284-308.
2011: Hedy L Kindler; Tatsuya Ioka; Dirk J Richel; Jaafar Bennouna; Richard Létourneau; Takuji Okusaka; Akihiro Funakoshi; Junji Furuse; Young Suk Park; Shinichi Ohkawa; Gregory M Springett; Harpreet S Wasan; Peter C Trask; Paul Bycott; Alejandro D Ricart; Sinil Kim; Eric Van Cutsem
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
The lancet oncology 2011;12(3):256-62.
2011: William F Sensakovic; Samuel G Armato; Adam Starkey; Hedy L Kindler; Wickii T Vigneswaran
Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication.
Academic radiology 2011;18(3):294-8.
2011: Sivakumar Loganathan; Rajani Kanteti; Shahid S Siddiqui; Essam El-Hashani; Maria Tretiakova; Hari Vigneswaran; Gustavo Cervantes; Viswanathan Natarajan; Aliya N Husain; Everett E Vokes; Hedy L Kindler; Ravi Salgia
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
Journal of carcinogenesis 2011;10():4.
2011: William F Sensakovic; Samuel G Armato; Christopher Straus; Rachael Y Roberts; Philip Caligiuri; Adam Starkey; Hedy L Kindler
Computerized segmentation and measurement of malignant pleural mesothelioma.
Medical physics 2011;38(1):238-44.
2010: Allyson J Ocean; Blase Polite; Paul Christos; Lisa Horvath; Anne Hamilton; Daniel Matulich; Helen X Chen; Joseph A Sparano; Hedy L Kindler
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
Clinical colorectal cancer 2010;9(5):290-6.
2010: Halla S Nimeiri; Deepti A Singh; Kristen Kasza; David A Taber; Rafat H Ansari; Everett E Vokes; Hedy L Kindler
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.
Investigational new drugs 2010;28(6):854-8.
2010: Hedy L Kindler; Donna Niedzwiecki; Donna Hollis; Susan Sutherland; Deborah Schrag; Herbert Hurwitz; Federico Innocenti; Mary Frances Mulcahy; Eileen O'Reilly; Timothy F Wozniak; Joel Picus; Pankaj Bhargava; Robert J Mayer; Richard L Schilsky; Richard M Goldberg
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3617-22.
2010: Eileen M O'Reilly; Donna Niedzwiecki; Margaret Hall; Donna Hollis; Tanios Bekaii-Saab; Timothy Pluard; Kathe Douglas; Ghassan K Abou-Alfa; Hedy L Kindler; Richard L Schilsky; Richard M Goldberg
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
The oncologist 2010;15(12):1310-9.
2009: Matthew H Kulke; Margaret A Tempero; Donna Niedzwiecki; Donna R Hollis; Hedy L Kindler; Michael Cusnir; Peter C Enzinger; Stefan M Gorsch; Richard M Goldberg; Robert J Mayer
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(33):5506-12.
2009: Ramesh K Ramanathan; Chandra P Belani; Deepti A Singh; Michael Tanaka; Heinz-Josef Lenz; Yun Yen; Hedy L Kindler; Syma Iqbal; Jeff Longmate; Philip C Mack; Georg Lurje; Regina Gandour-Edwards; Janet Dancey; David R Gandara
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Cancer chemotherapy and pharmacology 2009;64(4):777-83.
2009: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja M Flores; Joseph S Friedberg; Katherine M W Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):3007-13.
2009: Christine M Hartford; Apurva A Desai; Linda Janisch; Theodore Karrison; Victor M Rivera; Lori Berk; John W Loewy; Hedy L Kindler; Walter M Stadler; Heather L Knowles; Camille Bedrosian; Mark J Ratain
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1428-34.
2008: Leonardo Faoro; Sivakumar Loganathan; Maria Westerhoff; Rahul Modi; Aliya N Husain; Maria Tretiakova; Tanguy Seiwert; Hedy L Kindler; Everett E Vokes; Ravi Salgia
Protein kinase C beta in malignant pleural mesothelioma.
Anti-cancer drugs 2008;19(9):841-8.
2008: David M Jackman; Hedy L Kindler; Beow Y Yeap; Panos Fidias; Ravi Salgia; Joan Lucca; Linda K Morse; Patricia Ostler; Bruce E Johnson; Pasi A Janne
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Cancer 2008;113(4):808-14.
2008: Samir D Undevia; Federico Innocenti; Jacqueline Ramirez; Larry House; Apurva A Desai; Linda A Skoog; Deepti A Singh; Theodore Karrison; Hedy L Kindler; Mark J Ratain
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2008;44(12):1684-92.
2008: George R Simon; Claire F Verschraegen; Pasi A Janne; Corey J Langer; Afshin Dowlati; Shirish M Gadgeel; Karen Kelly; Gregory P Kalemkerian; Anne M Traynor; Guangbin Peng; John Gill; Coleman K Obasaju; Hedy L Kindler
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3567-72.
2008: Hedy L Kindler
Systemic treatments for mesothelioma: standard and novel.
Current treatment options in oncology 2008;9(2-3):171-9.
2008: Robert A Kratzke; Xiaofei Wang; Long Wong; Marian G Kratzke; Mark R Green; Everett E Vokes; Nicholas J Vogelzang; Hedy L Kindler; Jeffrey A Kern
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(4):417-21.
2008: Loren K Mell; David A Schomas; Joseph K Salama; Kiran Devisetty; Bulent Aydogan; Robert C Miller; Ashesh B Jani; Hedy L Kindler; Arno J Mundt; John C Roeske; Steven J Chmura
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
International journal of radiation oncology, biology, physics 2008;70(5):1431-7.
2008: Gavin J Gordon; Madhubalan Mani; Gautam Maulik; Lipi Mukhopadhyay; Beow Y Yeap; Hedy L Kindler; Ravi Salgia; David J Sugarbaker; Raphael Bueno
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Cancer chemotherapy and pharmacology 2008;61(4):549-58.
2008: Samuel G Armato; James J Entwisle; Mylene T Truong; Anna K Nowak; Giovanni Luca Ceresoli; Binsheng Zhao; Ripen Misri; Hedy L Kindler
Current state and future directions of pleural mesothelioma imaging.
Lung cancer (Amsterdam, Netherlands) 2008;59(3):411-20.
2008: Mitchell C Posner; Donna Niedzwiecki; Alan P Venook; Donna R Hollis; Hedy L Kindler; Edward W Martin; Richard L Schilsky; Richard M Goldberg; Robert J Mayer
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Annals of surgical oncology 2008;15(1):158-64.
2007: Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard Hochster; Scott Wadler; Paulo M Hoff; Nancy Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4557-61.
2007: Antonius A Miller; Daryl J Murry; Kouros Owzar; Donna Hollis; Lionel D Lewis; Hedy L Kindler; John L Marshall; Miguel A Villalona-Calero; Martin J Edelman; Raymond J Hohl; Stuart M Lichtman; Mark J Ratain
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3055-60.
2007: Kai Bickenbach; Rebecca Wilcox; Jula Veerapong; Hedy L Kindler; Mitchell C Posner; Amy Noffsinger; Kevin K Roggin
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2007;11(6):758-66.
2007: Hedy L Kindler
Pancreatic cancer: an update.
Current oncology reports 2007;9(3):170-6.
2006: Everett E Vokes; Michael C Perry; Hedy L Kindler; Mark R Green
The cancer and leukemia group B respiratory committee.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 2):3581s-8s.
2006: Geoffrey R Oxnard; Samuel G Armato; Hedy L Kindler
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
Lung cancer (Amsterdam, Netherlands) 2006;52(2):141-8.
2006: Samuel G Armato; Joseph L Ogarek; Adam Starkey; Nicholas J Vogelzang; Hedy L Kindler; Masha Kocherginsky; Heber MacMahon
Variability in mesothelioma tumor response classification.
AJR. American journal of roentgenology 2006;186(4):1000-6.
2006: Ramasamy Jagadeeswaran; Patrick C Ma; Tanguy Seiwert; Sujatha Jagadeeswaran; Osvaldo Zumba; Vidya Nallasura; Salman Ahmed; Rosangela Filiberti; Michela Paganuzzi; riccardo puntoni; Robert A Kratzke; Gavin J Gordon; David J Sugarbaker; Raphael Bueno; Varalakshmi Janamanchi; Vytautas P Bindokas; Hedy L Kindler; Ravi Salgia
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Cancer research 2006;66(1):352-61.
2005: Hedy L Kindler
Front-line therapy of advanced pancreatic cancer.
Seminars in oncology 2005;32(6 Suppl 9):S33-6.
2005: Jonathan E Dowell; Hedy L Kindler
Antiangiogenic therapies for mesothelioma.
Hematology/oncology clinics of North America 2005;19(6):1137-45, viii.
2005: Hedy L Kindler; Gregory Friberg; Deepti A Singh; Gershon Locker; Sreenivasa Nattam; Mark F. Kozloff; David A Taber; Theodore Karrison; Abraham H Dachman; Walter M Stadler; Everett E Vokes
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8033-40.
2005: Samuel G Armato; Geoffrey R Oxnard; Masha Kocherginsky; Nicholas J Vogelzang; Hedy L Kindler; Heber MacMahon
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
Academic radiology 2005;12(10):1301-9.
2005: Hedy L Kindler; Peter K Tothy; Robert Wolff; Richard A McCormack; James L Abbruzzese; Sridhar Mani; Kurombi Wade-Oliver; Everett E Vokes
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
Investigational new drugs 2005;23(5):489-93.
2005: Apurva A Desai; Hedy L Kindler; David A Taber; Edem Agamah; Sridhar Mani; Kurombi Wade-Oliver; Mark J Ratain; Everett E Vokes
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2005;56(4):421-6.
2005: Hedy L Kindler; Gregory Friberg; Linda Skoog; Kurombi Wade-Oliver; Everett E Vokes
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
American journal of clinical oncology 2005;28(4):340-4.
2005: Hedy L Kindler; James E Herndon; Chunfeng Zhang; Mark R Green
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
Lung cancer (Amsterdam, Netherlands) 2005;48(3):423-8.
2005: Hedy L Kindler
In focus: advanced pancreatic cancer.
Clinical advances in hematology & oncology : H&O 2005;3(5):420-2.
2005: Gregory Friberg; Hedy L Kindler
Chemotherapy for advanced pancreatic cancer: past, present, and future.
Current oncology reports 2005;7(3):186-95.
2005: Ramaswamy Govindan; Robert A Kratzke; James E Herndon; Gloria A Niehans; Robin Vollmer; Dorothy Watson; Mark R Green; Hedy L Kindler
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2300-4.
2004: Cathy Eng; Ramesh K Ramanathan; Ramesh K Ramathan; Michael K Wong; Scot C Remick; Lanting Dai; Kurombi Wade-Oliver; Sridhar Mani; Hedy L Kindler
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
American journal of clinical oncology 2004;27(6):565-9.
2004: Charles Rudin; John L Marshall; Chao Hui Huang; Hedy L Kindler; Chuanbo Zhang; Deepak Kumar; Prafulla C Gokhale; Joyce Steinberg; Steve Wanaski; Usha N Kasid; Mark J Ratain
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7244-51.
2004: Samir D Undevia; Hedy L Kindler; Linda Janisch; S C Olson; Richard L Schilsky; Nicholas J Vogelzang; K A Kimmel; T A Macek; Mark J Ratain
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(11):1705-11.
2004: Manisha H Shah; Donn Young; Hedy L Kindler; Iain Webb; Barbara Kleiber; John Wright; Michael R Grever
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6111-8.
2004: Hedy L Kindler
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Lung cancer (Amsterdam, Netherlands) 2004;45 Suppl 1():S125-7.
2004: Hedy L Kindler; Anjali Avadhani; Kurombi Wade-Oliver; Theodore Karrison; Sridhar Mani; Everett E Vokes
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Investigational new drugs 2004;22(3):323-7.
2004: Hedy L Kindler
The emerging role of pemetrexed for the treatment of malignant mesothelioma.
Oncology (Williston Park, N.Y.) 2004;18(8 Suppl 5):49-53.
2004: Christopher W Ryan; Nicholas J Vogelzang; Everett E Vokes; Hedy L Kindler; Samir D Undevia; Rod A Humerickhouse; Amy K André; Qiang Wang; Robert A Carr; Mark J Ratain
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4406-11.
2004: Paul R Helft; Richard L Schilsky; Frank J Hoke; Daphne Williams; Hedy L Kindler; Evie Sprague; Mark DeWitte; Helen K Martino; John Erickson; Lini Pandite; Mark Russo; John M Lambert; Maria Howard; Mark J Ratain
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4363-8.
2004: Milica Medved; Gregory S Karczmar; Cheng Yang; James J Dignam; Thomas F Gajewski; Hedy L Kindler; Everett E Vokes; Peter MacEneany; Myrosia T Mitchell; Walter M Stadler
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
Journal of magnetic resonance imaging : JMRI 2004;20(1):122-8.
2004: Cathy Eng; Hedy L Kindler; S Nattam; Rafat H Ansari; Kristen Kasza; Kurombi Wade-Oliver; Everett E Vokes
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(6):928-32.
2004: Samuel G Armato; Geoffrey R Oxnard; Heber MacMahon; Nicholas J Vogelzang; Hedy L Kindler; Masha Kocherginsky; Adam Starkey
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
Medical physics 2004;31(5):1105-15.
2004: Gregory A Otterson; James E Herndon; Dorothy Watson; Mark R Green; Hedy L Kindler
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
Lung cancer (Amsterdam, Netherlands) 2004;44(2):251-9.
2003: M Aklilu; Hedy L Kindler; Ross C Donehower; Sridhar Mani; Everett E Vokes
Phase II study of flavopiridol in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1270-3.
2003: Wallace Akerley; James E Herndon; Merrill J Egorin; Alan P Lyss; Hedy L Kindler; Dianne M Savarese; Carol A Sherman; D Marc Rosen; Donna Hollis; Mark J Ratain; Mark R Green
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Cancer 2003;97(10):2480-6.
2003: Giorgio V Scagliotti; Dong M Shin; Hedy L Kindler; Michael J Vasconcelles; Uwe Keppler; Christian Manegold; Howard Burris; Ulrich Gatzemeier; Johannes Blatter; James T Symanowski; James J Rusthoven
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1556-61.
2002: Hedy L Kindler
Pemetrexed in pancreatic cancer.
Seminars in oncology 2002;29(6 Suppl 18):49-53.
2002: Hedy L Kindler
The pemetrexed/gemcitabine combination in pancreatic cancer.
Cancer 2002;95(4 Suppl):928-32.
2002: Aimery de Gramont; Hedy L Kindler
Pemetrexed in patients with gastrointestinal carcinoma.
Seminars in oncology 2002;29(2 Suppl 5):42-9.
2002: Sridhar Mani; Charles Rudin; Katie Kunkel; Jon T Holmlund; Richard S Geary; Hedy L Kindler; F Andrew Dorr; Mark J Ratain
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1042-8.
2002: Anna K Nowak; Richard A Lake; Hedy L Kindler; Bruce W S Robinson
New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.
Seminars in oncology 2002;29(1):82-96.
2002: Hedy L Kindler; Jan P van Meerbeeck
The role of gemcitabine in the treatment of malignant mesothelioma.
Seminars in oncology 2002;29(1):70-6.
2002: Richard L Schilsky; Donna Bertucci; Nicholas J Vogelzang; Hedy L Kindler; Mark J Ratain
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):582-7.
2001: Hedy L Kindler; K L Shulman
Metastatic colorectal cancer.
Current treatment options in oncology 2001;2(6):459-71.
2001: C Eng; Hedy L Kindler; Richard L Schilsky
Oral fluoropyrimidine treatment of colorectal cancer.
Clinical colorectal cancer 2001;1(2):95-103.
2001: Hedy L Kindler; Frederick Millard; James E Herndon; Nicholas J Vogelzang; Y Suzuki; Mark R Green
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
Lung cancer (Amsterdam, Netherlands) 2001;31(2-3):311-7.
2000: Hedy L Kindler
Malignant pleural mesothelioma.
Current treatment options in oncology 2000;1(4):313-26.
1999: Hedy L Kindler; Chandra P Belani; James E Herndon; Nicholas J Vogelzang; Y Suzuki; Mark R Green
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
Cancer 1999;86(10):1985-91.
1998: Hedy L Kindler; Mark G Kris; I E Smith; Vincent A Miller; Stefan C Grant; J B Krebs; G A Ross; M L Slevin
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
American journal of clinical oncology 1998;21(5):438-41.
1997: Vincent A Miller; Kenneth K Ng; Stefan C Grant; Hedy L Kindler; Barbara Pizzo; Robert T Heelan; R von Roemeling; Mark G Kris
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1269-71.